Clinical Scorecard: FDA Clears Avulux Migraine Lenses
At a Glance
| Category | Detail |
|---|---|
| Condition | Migraine-associated light sensitivity |
| Key Mechanisms | Precision light-filtering lenses designed to block specific wavelengths of light (480 nm and 590 nm) while allowing the rest of the visible spectrum to pass through. |
| Target Population | Patients aged 12 years and older with episodic migraine |
| Care Setting | Eye care providers and optical practices |
Key Highlights
- FDA granted De Novo marketing authorization for Avulux lenses.
- Lenses block light at 480 nm and 590 nm, targeting light sensitivity.
- Up to 90% of migraine patients experience light sensitivity.
- Lenses are available over-the-counter and can be prescribed.
- More than 50,000 users have been dispensed the lenses.
Guideline-Based Recommendations
Diagnosis
- Patients should be diagnosed with episodic migraine and clinically significant light sensitivity.
Management
- Patients are advised to continue standard migraine treatments alongside the use of Avulux lenses.
Monitoring & Follow-up
- Monitor the effectiveness of the lenses in reducing light sensitivity and migraine attacks.
Risks
- Potential for light sensitivity to trigger migraine attacks remains.
Patient & Prescribing Data
Adolescents and adults with episodic migraine experiencing light sensitivity.
Lenses are intended to complement existing migraine treatments, not replace them.
Clinical Best Practices
- Educate patients on the use of Avulux lenses in conjunction with prescribed migraine medications.
- Assess the impact of light sensitivity on patients' migraine frequency and severity.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
